BMS Boosts Governance & Rare‑Disease Pipeline for Stronger Shareholder Value
New BMS board hires boost governance & capital strategy while rare‑lung drug advances toward orphan status, promising $150‑$250 M launch revenue and strong shareholder upside.
4 minutes to read


